Tech Company Financing Transactions

Volastra Therapeutics Funding Round

Volastra Therapeutics, based in New York, received $60 million from Arch Venture Partners, Eli Lilly and Company and Polaris Partners.

Transaction Overview

Announced On
3/7/2023
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to support clinical development of its portfolio of KIF18A inhibitors as well as advancement of a pipeline of research programs targeting chromosomally unstable cancers.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1361 Amsterdam Ave. 520
New York, NY 10027
USA
Email Address
Overview
Volastra Therapeutics is pioneering novel approaches to halt or prevent cancer metastasis, one of the major unsolved challenges in cancer treatment. Co-founders Lewis Cantley, Ph.D., Olivier Elemento, Ph.D. and Samuel Bakhoum, M.D., Ph.D., made seminal discoveries about the role of chromosomal instability in driving cancer spread.
Profile
Volastra Therapeutics LinkedIn Company Profile
Social Media
Volastra Therapeutics Company Twitter Account
Company News
Volastra Therapeutics News
Facebook
Volastra Therapeutics on Facebook
YouTube
Volastra Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Charles Hugh-Jones
  Charles Hugh-Jones LinkedIn Profile  Charles Hugh-Jones Twitter Account  Charles Hugh-Jones News  Charles Hugh-Jones on Facebook
Chief Scientific Officer
Michael Su
  Michael Su LinkedIn Profile  Michael Su Twitter Account  Michael Su News  Michael Su on Facebook
Vice President
Rumin Zhang
  Rumin Zhang LinkedIn Profile  Rumin Zhang Twitter Account  Rumin Zhang News  Rumin Zhang on Facebook
VP - Operations
Diane Tager
  Diane Tager LinkedIn Profile  Diane Tager Twitter Account  Diane Tager News  Diane Tager on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/7/2023: Assured Allies venture capital transaction
Next: 3/7/2023: Growfin venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary